Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck Secures Up to $2.13B Deal for Preclinical Cancer Drug SPR2015

Guavy AI Editorial Team
Instruments
MRK
Share

Pharmaceutical giant Merck & Co., Inc. (NYSEMRK) has closed a licensing deal with SciBrunch Therapeutics Co., Ltd. for the preclinical KRAS G12D cancer drug, SPR2015.

The agreement grants Merck exclusive rights to develop and commercialize SPR2015 worldwide, with a potential value of up to $2.13 billion.

The upfront payment is $400 million, which will be included in Merck's third-quarter 2026 GAAP and non-GAAP results as a pre-tax charge of approximately $0.13 per share.

SPR2015 has shown nanomolar antiproliferative activity in KRAS G12D-mutant cell lines, with selectivity over cells carrying unmutated KRAS.

More on Stocks

Stocks just now

Nvidia Launches Open Agent Safety Platform Amid Growing Concerns Over Rogue AI

Stocks 1m ago

Nvidia Unveils Open Agent Safety Platform After AI Model Containment Failures

Stocks 2m ago

Cisco and Kenya Deepen Partnership on Digital Transformation and AI Skills

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy